Direct buyers file amended US complaint against Takeda, Upsher-Smith over Dexilant
MLex Summary: Direct buyers of Dexilant filed an amended US complaint accusing Takeda Pharmaceutical and Upsher-Smith Laboratories of entering into an illegal reverse payment agreement to limit competition from generic equivalents.See attached...To view the full article, register now.
Already a subscriber? Click here to view full article